文献速递消化道肿瘤与早癌

聚肌胞苷酸激活固有-适应性免疫机制揭示富含间质结肠癌预防复发的治疗脆弱性

Activation of innate-adaptive immune machinery by poly(I:C) exposes a therapeutic vulnerability to prevent relapse in stroma-rich colon cancer.
PubMed 文献 · Gut · 2022-04-27

该研究针对富含间质的II/III期结肠癌复发率高、辅助化疗反应有限的问题,在富含间质/高成纤维细胞(HiFi)亚型中鉴定并验证了基于STAT1相关信号的HiFi特异性预后特征(HPS),High-HPS对比Low-HPS的HR为0.093(CI 0.019至0.466)。体外和体内模型显示TLR3激动剂聚肌胞苷酸(poly(I:C))可提升HPS信号和抗原加工表型,在富含间质结肠癌体内模型中显著增加全身细胞毒性T细胞活性(p<0.05)并减少肝转移(p<0.0002)。

要点

  • 在富含间质/高成纤维细胞结肠癌亚型中鉴定并验证了基于STAT1相关信号的HiFi特异性预后特征(HPS)。
  • High-HPS对比Low-HPS的HR为0.093(CI 0.019至0.466)。
  • 聚肌胞苷酸在体内模型中显著增加全身细胞毒性T细胞活性(p<0.05)并减少肝转移(p<0.0002)。

核心结论

  • 该研究揭示了新的生物学见解,为降低预后最差结肠癌患者的复发率提供了新的治疗选择。

研究设计与样本

  • 按间质含量对人肿瘤队列进行分层,以识别富含间质肿瘤中驱动复发的基础生物学和潜在治疗脆弱性。
  • 基于人肿瘤的发现和独立临床验证后,使用一系列体外和富含间质体内模型测试并验证提升与减少复发相关生物学的治疗潜力。

主要发现

  • 在富含间质/高成纤维细胞(HiFi)亚型中鉴定并验证了HiFi特异性预后特征(HPS)的临床价值,该特征基于STAT1相关信号对肿瘤进行分层(High-HPS对比Low-HPS的HR为0.093,CI 0.019至0.466)。
  • HPS与富含间质结肠癌中离散免疫谱系内的抗原加工和呈递相关,位于双链RNA和病毒应答信号下游。
  • 聚肌胞苷酸治疗在体外和体内模型中提升了HPS信号和抗原加工表型。
  • 在富含间质结肠癌体内模型中,聚肌胞苷酸治疗显著增加全身细胞毒性T细胞活性(p<0.05)并减少肝转移(p<0.0002)。

关键数值与推荐

  • High-HPS对比Low-HPS的HR为0.093(CI 0.019至0.466)。
  • 聚肌胞苷酸治疗显著增加全身细胞毒性T细胞活性(p<0.05)。
  • 聚肌胞苷酸治疗显著减少肝转移(p<0.0002)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Stroma-rich tumours represent a poor prognostic subtype in stage II/III colon cancer (CC), with high relapse rates and limited response to standard adjuvant chemotherapy. DESIGN: To address the lack of efficacious therapeutic options for patients with stroma-rich CC, we stratified our human tumour cohorts according to stromal content, enabling identification of the biology underpinning relapse and potential therapeutic vulnerabilities specifically within stroma-rich tumours that could be exploited clinically. Following human tumour-based discovery and independent clinical validation, we use a series of in vitro and stroma-rich in vivo models to test and validate the therapeutic potential of elevating the biology associated with reduced relapse in human tumours. RESULTS: By performing our analyses specifically within the stroma-rich/high-fibroblast (HiFi) subtype of CC, we identify and validate the clinical value of a HiFi-specific prognostic signature (HPS), which stratifies tumours based on STAT1-related signalling (High-HPS v Low-HPS=HR 0.093, CI 0.019 to 0.466). Using in silico, in vitro and in vivo models, we demonstrate that the HPS is associated with antigen processing and presentation within discrete immune lineages in stroma-rich CC, downstream of double-stranded RNA and viral response signalling. Treatment with the TLR3 agonist poly(I:C) elevated the HPS signalling and antigen processing phenotype across in vitro and in vivo models. In an in vivo model of stroma-rich CC, poly(I:C) treatment significantly increased systemic cytotoxic T cell activity (p<0.05) and reduced liver metastases (p<0.0002). CONCLUSION: This study reveals new biological insight that offers a novel therapeutic option to reduce relapse rates in patients with the worst prognosis CC.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Corry SM, McCorry AM, Lannagan TR, et al. Activation of innate-adaptive immune machinery by poly(I:C) exposes a therapeutic vulnerability to prevent relapse in stroma-rich colon cancer. Gut. 2022. PMID: 35477539. doi:10.1136/gutjnl-2021-326183

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。